ENTR-501

About Entrada Therapeutics

Entrada Therapeutics is focused on transforming the treatment of devastating diseases by enabling the intracellular delivery of therapeutic molecules. The company's core Endosomal Escape Vehicle (EEV) platform facilitates the delivery of proteins, peptides, oligonucleotides, and other cargo into the cytoplasm of target cells, opening new avenues for treating conditions with intracellular targets. Entrada has advanced multiple programs into clinical development, secured strategic partnerships with major pharmaceutical companies, and operates as a publicly traded entity on NASDAQ. The company's mission is to leverage its platform to create a broad pipeline of novel therapeutics for patients with high unmet medical needs.

Therapeutic Areas